Kenneth Fuh, PhD
Research Scientist, Syantra Diagnostics,
Calgary, Canada.
Dr. Kenneth Fuh holds a PhD in Biomedical Engineering from the University of Calgary, an MSc in Biotechnology from the University of Manchester, United Kingdom and a BSc (Honours) in Biochemistry from the University of Buea, Cameroon.
Ken is involved in biomedical engineering approaches to study cancer metastasis, with emphasis on Epithelial-to-Mesenchymal Transition – a phenotypic change that occurs during cancer progression and wound healing. Ken has a particular interest in bioinformatics and network biology approaches to study diseases such as wound infections, with the goal of investigating better diagnostic approaches and more efficient therapeutic options. Through these, he has been actively involved in novel assay development and biotechnology commercialization.
Ken has presented his work nationally and internationally at conferences including the Molecular Medicine Tri-Conference, Biomedical Engineering Society Conference and the Symposium on Therapeutic Protein Production. He is first author of a United States’ provisional patent application and a recipient of several prestigious awards including the Queen Elizabeth Scholarship (2013 – 2015), Alberta Graduate Student Scholarship (2014) and funding from the Commonwealth Scholarship and Fellowship Plan (2009 – 2011). Dr. Fuh is a member of several professional bodies including The Biomedical Engineering Society and The Canadian Medical and Biological Engineering Society.
